Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
Extraordinary Picks for Home Apparatuses: Making Life Simpler- Novartis to build manufacturing hub in North Carolina, creating 700 jobs
- Journalists killed by Israeli strike in southern Lebanon
- Russia earning billions from Hormuz blockade, German trade body says
- Cyclone causes blackout, flight chaos in Brazil's Sao Paulo
- Figure out How to Explore the Infotainment Framework in the Slam 1500.
- Germany paves the way for tighter EU asylum rules
- Putting pig organs in people is OK in the US, but growing human organs in pigs is not – why is that?
- Trump declares Christmas Eve and Dec. 26 federal holidays: What does that mean?
